IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 1422.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 14-Jul-2016
Nicotine & Tobacco Research
Public health benefits of e-cigarette use tend to outweigh the harms
A modeling study by top tobacco control experts finds that e-cigarettes are likely to provide public health benefits based on 'conservative estimates' of the likely uptake of vaping and smoking by adolescents and young adults. 'Our study indicates that, considering a broad range of reasonable scenarios, e-cigarettes are likely to reduce cigarette smoking and not lead to offsetting increases in harm from the use of e-cigarettes and more deadly cigarettes,' says the lead author.
NIH/National Institute on Drug Abuse, NIH/National Cancer Institute

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 13-Jul-2016
The Lancet
As overweight and obesity increase, so does risk of dying prematurely
Being overweight or obese is associated with a higher risk of dying prematurely than being normal weight -- and the risk increases with additional pounds, according to a large international collaborative study led by researchers at the Harvard T.H. Chan School of Public Health and the University of Cambridge, UK. The findings contradict recent reports that suggest a survival advantage to being overweight -- the so-called 'obesity paradox.'
National Institutes of Health, UK Medical Research Council, British Heart Foundation, British Heart Foundation Cambridge Cardiovascular Centre of Excellence, UK National Institute for Health Research Cambridge Biomedical Research Centre

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-8413
Harvard T.H. Chan School of Public Health

Public Release: 13-Jul-2016
Scientific Reports
A 'key' to metastasis formation
Hokkaido University researchers identified a 'key' molecule that allows tumor cells to break into the bloodstream and form metastases.

Contact: Naoki Namba
pr@oia.hokudai.ac.jp
81-117-068-034
Hokkaido University

Public Release: 13-Jul-2016
The Allied Genetics Conference
Overcoming barriers in the quest to starve tumors of blood supply
One of the most exciting strategies researchers are pursuing for fighting cancer is to cut off the blood supply of cancerous cells. However, many initially-promising therapies have failed in part because tumor cells counteract these therapies by increasing their production of 'pro-angiogenic' proteins that promote new blood vessel growth and boost tumor blood supply. In a new study, researchers have found a way to turn the tables on this process.

Contact: Andrew Noble
TAGCPress@genetics-gsa.org
Genetics Society of America

Public Release: 13-Jul-2016
New England Journal of Medicine
Immunotherapy benefits relapsed stem cell transplant recipients
Dana-Farber Cancer Institute study published in the New England Journal of Medicine suggests that using repeated doses of an immunotherapy drug can restore a complete remission for some relapsed stem cell transplant recipients.
National Institutes of Health, NIH/National Cancer Institute Cancer Therapy Evaluation Program, Leukemia & Lymphoma Society Therapy Accelerator Program

Contact: John Noble
johnw_noble@dfci.harvard.edu
617-632-5784
Dana-Farber Cancer Institute

Public Release: 13-Jul-2016
ACS Central Science
Local drug activation at solid tumor sites
Sarcoma is an aggressive form of cancer responsible for up to 20 percent of childhood cancers. Tumors often first appear in the extremities and the abdomen. Surgery is a primary treatment, but it often is combined with chemotherapy. This week in ACS Central Science, researchers propose a scheme to target chemotherapy medications specifically to sarcomas, leading to greater efficacy and fewer side effects.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 13-Jul-2016
Scientific Reports
Simplifying access to gene testing for women with ovarian cancer
A new streamlined approach to genetic testing for women with ovarian cancer provides testing rapidly and affordably, allowing many more patients to benefit from personalized cancer management and their relatives to benefit from cancer prevention strategies.
Wellcome Trust

Contact: Henry French
henry.french@icr.ac.uk
020-715-35582
Institute of Cancer Research

Public Release: 13-Jul-2016
The Allied Genetics Conference
First drug target identified for children with rare type of brain tumor
Primitive neuroectodermal tumors are the largest group of malignant brain tumors in children. They can arise from the brain's cerebellum or from tissue located throughout the central nervous system. Little is known about how CNS-PNETs develop, although these tumors are more aggressive than other PNETs and have an overall survival rate of only about 20 percent. In a new study, researchers have identified a possible target for a new CNS-PNET therapy.

Contact: Andrew Noble
TAGCPress@genetics-gsa.org
415-722-2129
Genetics Society of America

Public Release: 13-Jul-2016
Current Cancer Drug Targets
Recent advances in site specific conjugations of antibody drug conjugates
Antibody-drug conjugates take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent cytotoxic drugs selectively to antigen-expressing tumor cells.

Contact: Faizan ul Haq
faizan@benthamscience.org
Bentham Science Publishers

Public Release: 13-Jul-2016
Nature
In the gut, nervous cells are the 'eyes and ears' of the immune system
A team of scientists in Portugal has discovered, in the mouse gut, a novel process that protects the bowel's lining against inflammation and microbial aggressions -- and fights them when they arise. And, most surprisingly, they have shown that this mechanism is under the control of the intestinal nervous system -- the so-called 'second brain.'

Contact: Maria Joao Soares
mjsoares@jlma.pt
351-914-237-487
JLM&A, SA

Public Release: 13-Jul-2016
Oncotarget
Study finds first evidence that PD-1 antibody could help men with metastatic prostate cancer
A new study from the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. It is a surprising turnaround because prior results in men with aggressive, advanced-stage prostate cancer showed no evidence of anti-tumor activity with immune therapies that work by blocking PD-1 signals.
Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp, Bloomberg Kimmel Institute

Contact: Amanda Gibbs
gibbam@ohsu.edu
503-494-5640
Oregon Health & Science University

Public Release: 13-Jul-2016
Cancer Research
UNC professor identifies research priorities for National Institutes of Health
Nigel Key, MB, ChB, FRCP, director of the UNC Hemophilia and Thrombosis Center, is lead author of an advisory opinion on research priorities to address VTE in cancer patients.

Contact: Caroline Curran
caroline.curran@unchealth.unc.edu
984-974-1146
University of North Carolina Health Care

Public Release: 13-Jul-2016
Current Drug Targets
In cancer and aging, interconnected roles for apoptosis and cellular senescence
A new review explores the mechanisms activating cell death and blocking proliferation of mutated cells, with a view towards creating more effective therapies combining both programs.

Contact: Faizan ul Haq
faizan@benthamscience.org
Bentham Science Publishers

Public Release: 13-Jul-2016
Nature Communications
Penn preclinical study outlines cardiovascular side effects of breast cancer drug
A receptor protein that is the target of the breast cancer drug trastuzumab (Herceptin) is needed for proper heart blood-vessel development. These discoveries have implications for better understanding the cardiovascular side effects of trastuzumab commonly used for cancer and provide an example of integration at the molecular level of pathways involved in tissue growth and blood-vessel patterning.
National Institute of Health, Spain Fund, Cotswold Foundation, WW Smith Endowed Chair

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 13-Jul-2016
Scientific Reports
Crossing the barriers: Pharmacy researchers improving drug delivery
A number of drugs -- from insulin to cancer chemotherapy -- can be delivered only via injections, which are far more difficult for patients than taking a simple tablet or pill. It can also be more expensive, as this type of drug has to be prepared very carefully and sometimes can only be administered in a clinical setting.

Contact: Holly Shive
hshive@tamhsc.edu
979-436-0613
Texas A&M University

Public Release: 13-Jul-2016
Americans say political candidates are not listening to their health concerns
A strong majority of Americans (81 percent) say medicines available today have improved their quality of life and even more (91 percent) say it is important to develop better medicines for conditions we currently treat, according to a new national public opinion survey commissioned by Research!America. But many respondents say candidates for President and Congress have done a poor job relating to the health expectations of Americans.

Contact: Anna Briseno
abriseno@researchamerica.org
571-482-2737
Research!America

Public Release: 13-Jul-2016
Journal of Applied Physiology
Fat cells may play key role in battle against breast cancer: York U study
New research led by York University Professor Michael Connor highlights how fat cells could help determine the most effective way to fight breast cancer; including using exercise to combat the disease. For nearly a half century, researchers have studied the links between obesity and breast cancer. This recent study has revealed specifically that adiponectin and leptin are possible reasons for poorer response to therapy and higher risk of death in obese persons than in others.

Contact: Gloria Suhasini
suhasini@yorku.ca
416-736-2100 x22094
York University

Public Release: 13-Jul-2016
Journal of Thoracic Oncology
Nivolumab cost-effectiveness improves by selecting non-squamous NSCLC PD-L1+ patients
Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price.

Contact: Jeff Wolf
Jeff.Wolf@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 12-Jul-2016
Nature Communications
Red hair gene variation drives up skin cancer mutations
For the first time, researchers at the Wellcome Trust Sanger Institute and University of Leeds have proved that gene variants associated with red hair, pale skin and freckles are linked to a higher number of genetic mutations in skin cancers. The burden of mutations associated with these variants is comparable to an extra 21 years of sun exposure in people without this variant.
Cancer Research UK, Wellcome Trust

Contact: Samantha Wynne
press.office@sanger.ac.uk
122-349-2368
Wellcome Trust Sanger Institute

Public Release: 12-Jul-2016
Cancer Letters
As body mass index increases, so does spread of multiple myeloma
In a new study, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma.

Contact: Rebecca Basu
basu@american.edu
202-885-5950
American University

Public Release: 12-Jul-2016
Proceedings of the National Academy of Sciences
Newly discovered features of collagen may help shed light on disease processes
Scientists at the National Institutes of Health are reporting new, unexpected details about the fundamental structure of collagen, the most abundant protein in the human body. In lab experiments, they demonstrated that collagen, once viewed as inert, forms structures that regulate how certain enzymes break down and remodel body tissue. The finding of this regulatory system provides a molecular view of the potential role of physical forces at work in heart disease, cancer, arthritis, and other disease-related processes, they say.

Contact: NHLBI Engagement and Media Relations Branch
nhlbi_news@nhlbi.nih.gov
301-496-5449
NIH/National Heart, Lung and Blood Institute

Public Release: 12-Jul-2016
Oncotarget
Mayo Clinic researchers identify potential immunotherapy drug combination
A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, published in the July 12 edition of the online journal Oncotarget.

Contact: Julie Janovsky-Mason
newsbureau@mayo.edu
480-301-6173
Mayo Clinic

Public Release: 11-Jul-2016
Journal of Nuclear Medicine
PET/MRI: A one-stop imaging test to detect prostate cancer?
A University of Michigan study published in the July issue of The Journal of Nuclear Medicine reports that the addition of molecular imaging based on F-18-choline positron emission tomography (PET) improves the identification of significant prostate cancer over multi-parametric prostate magnetic resonance imaging (mpMRI) alone for targeted transrectal prostate biopsies.
Department of Defense, National Institutes of Health, NIH/National Cancer Institute

Contact: Laurie Callahan
lcallahan@snmmi.org
Society of Nuclear Medicine

Public Release: 11-Jul-2016
Chemical Research in Toxicology
Hops extract studied to prevent breast cancer
An enriched hops extract activates a chemical pathway in cells that could help prevent breast cancer, according to new laboratory findings from the UIC/NIH Center for Botanical Dietary Supplements Research at the University of Illinois at Chicago.
NIH Office of Dietary Supplements, National Center for Complementary and Integrative Health

Contact: Sam Hostettler
samhos@uic.edu
312-355-2522
University of Illinois at Chicago

Public Release: 11-Jul-2016
Gastrointestinal Endoscopy
Study sheds light on true risk for pancreatic cancer in patients with cysts
A look back at more than half a million patient records has established that patients with pancreatic cysts have a significantly higher overall risk of pancreatic cancer compared to those without such cysts, according to a study in the July issue of GIE: Gastrointestinal Endoscopy, the journal of the American Society for Gastrointestinal Endoscopy (ASGE).

Contact: Gina Steiner
gsteiner@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy

Showing releases 126-150 out of 1422.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

  Search News Releases

     

 

EurekAlert!